PT  - JOURNAL ARTICLE
AU  - Megha L. Mehrotra
AU  - Esther Lim
AU  - Katherine Lamba
AU  - Amanda Kamali
AU  - Kristina W. Lai
AU  - Erika Meza
AU  - Irvin Szeto
AU  - Peter Robinson
AU  - Cheng-ting Tsai
AU  - David Gebhart
AU  - Noemi Fonseca
AU  - Andrew B. Martin
AU  - Catherine Ley
AU  - Steve Scherf
AU  - James Watt
AU  - David Seftel
AU  - Julie Parsonnet
AU  - Seema Jain
TI  - CalScope: Monitoring SARS-CoV-2 Seroprevalence from Vaccination and Prior Infection in Adults and Children in California May 2021– July 2021
AID  - 10.1101/2021.12.09.21267565
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.12.09.21267565
4099  - http://medrxiv.org/content/early/2021/12/11/2021.12.09.21267565.short
4100  - http://medrxiv.org/content/early/2021/12/11/2021.12.09.21267565.full
AB  - Importance Understanding how SARS-CoV-2 seroprevalence varies regionally across California is critical to the public health response to the pandemic.Objective To estimate how many Californians have antibodies against SARS-CoV-2 from prior infection or vaccination.Design Wave 1 of CalScope: a repeated cross-sectional serosurvey of adults and children enrolled between April 20, 2021 and June 16, 2021.Setting A population-based random sample of households in seven counties in California (Alameda, El Dorado, Kern, Los Angeles, Monterey, San Diego, and Shasta) were invited to complete an at-home SARS-CoV-2 antibody test and survey instrument.Participants Invitations were sent to 200,000 randomly selected households in the seven counties. From each household, 1 adult (18 years and older) and 1 child (aged 6 months to 17 years) could enroll in the study. There were no exclusion criteria.Main Outcome(s) and Measures All specimens were tested for antibodies against the nucleocapsid and spike proteins of SARS-CoV-2. The primary outcome was serostatus category, which was determined based on antibody test results and self-reported vaccination status: seronegative, antibodies from infection only, antibodies from infection and vaccination, and antibodies from vaccination alone. We used inverse probability of selection weights and iterative proportional fitting to account for non-response.Results 11,161 households enrolled in wave 1 of CalScope, with 7,483 adults and 1,375 children completing antibody testing. As of June 2021, 27% (95%CI [23%, 31%]) of adults and 30% (95%CI [24%, 36%]) of children had evidence of prior SARS-CoV-2 infection; 33% (95%CI [28%, 37%]) of adults and 57% (95%CI [48%, 66%]) of children were seronegative. Serostatus varied regionally. Californians 65 years or older were most likely to have antibodies from vaccine alone (59%; 95%CI [48%, 69%]) and children between 5-11 years old were most likely to have antibodies from prior infection alone (36%; 95%CI [21%, 52%]).Conclusions and Relevance As of June 2021, a third of adults in California and most children under 18 remained seronegative. Seroprevalence varied regionally and by demographic group, suggesting that some regions or populations might remain more vulnerable to subsequent surges than others.Question What is the prevalence of vaccine and infection derived antibodies against SARS-CoV-2 in adults and children in California?Findings In this population-based serosurvey that included 11,161 households, as of June 2021, 33% of adults and 57% of children were seronegative; 18% of adults and 26% of children had antibodies from infection alone; 9% of adults and 5% of children had antibodies from both infection and vaccination; and 41% of adults and 13% of children had antibodies from vaccination alone.Meaning Serostatus varied considerably across geographic regions, suggesting that certain areas might be at increased risk for future COVID-19 surges.Competing Interest StatementThe authors have declared no competing interest.Funding Statementthe Centers for Disease ControlAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Committee for Protection of Human Subjects of the State of California waived ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors